CE18 - Innovation biomédicale

Therapeutic human monoclonal antibodies against multidrug resistant bacteria via combined high-potential target identification, single B cell antibody isolation and structural approaches – HUMABACT

Submission summary

Multi drug resistant (MDR) bacteria, notably Klebsiella pneumoniae (Kp) and Pseudomonas aeruginosa (Pa), are a major global threat. The development of alternative anti-infectious therapies is thus crucial. In this respect, monoclonal antibodies (mAbs) targeting bacterial virulence factors offer highly promising perspectives. To accelerate the discovery of antibacterial therapeutic mAbs, we propose a highly innovative pipeline combining: i) the identification - through combined reverse vaccinology and functional genetics - and careful selection of virulence factors as high potential targets and design of associated robust functional assays; ii) the rational design, based on structural studies, of corresponding baits for an optimized specific B cell isolation; and iii) state of the art mAb isolation methods from single B cells from infected and convalescent individuals. The program will yield a large panel of fully human mAbs with strong therapeutic potential against Pa and Kp.

Project coordination


The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.


IBS Commissariat à l'énergie atomique et aux énergies alternatives
IBS Commissariat à l'énergie atomique et aux énergies alternatives

Help of the ANR 679,963 euros
Beginning and duration of the scientific project: September 2022 - 48 Months

Useful links

Explorez notre base de projets financés



ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter